TY - JOUR
T1 - Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
AU - Buonaguro, Luigi
AU - Buonaguro, Franco M.
PY - 2020/5/12
Y1 - 2020/5/12
N2 - The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
AB - The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
UR - http://www.scopus.com/inward/record.url?scp=85085153208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085153208&partnerID=8YFLogxK
U2 - 10.1186/s13027-020-00302-x
DO - 10.1186/s13027-020-00302-x
M3 - Article
AN - SCOPUS:85085153208
VL - 15
JO - Infectious Agents and Cancer
JF - Infectious Agents and Cancer
SN - 1750-9378
IS - 1
M1 - 32
ER -